// App-Quantinova.ai

P149 : An Exploratory Trial Assessing Finger Perfusion, Raynaud’s Condition Score and Safety, Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud's Phenomenon Secondary to Systemic Sclerosis

Researchers

Presenter

  • Ariane L Herrick

Principal Investigators

  • Andrea Murray

  • Graham Dinsdale

  • Joanne Manning

  • Chukwuma Chukwu

  • Marcia Alvarez Fernandez

  • James R Seibold

  • Fredrik Tiberg

Medical Centers

  • Rheumatology, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom

  • Clinical Research Facility, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom

  • Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

  • Clinical Development, Camurus AB, Lund, Sweden

Locations

  • United Kingdom

  • United States

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Autoimmune (AI)

Disease

  • Raynaud syndrome

  • Scleroderma

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Treprostinil

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved